Price (delayed)
$2.45
Market cap
$156.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$140M
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical
There are no recent dividends present for LRMR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.